Source: International Congress 2017 – Discussion of techniques and technologies in lung function



Rating:

Share or cite this content

Citations should be made in the following way:
T. Radtke (Zürich, Switzerland). Intra-session and inter-session variability of nitric oxide pulmonary diffusing capacity in patients with cystic fibrosis. 3006

Member's Comments

No comment yet.

Related content which might interest you: Lung diffusing capacity for nitric oxide and carbon monoxide: methodological issues and reproducibility in patients with cystic fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 325s Year: 2007 A small amount of inhaled nitric oxide does not increase lung diffusing capacity Source: Eur Respir J 2006; 27: 1251-1257 Year: 2006 Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular impairments Source: Eur Respir J 2009; 34: 117-124 Year: 2009 Effect of inhaled L-arginine on airway nitric oxide in cystic fibrosis patients Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle Year: 2005 Reduced exhaled nitric oxide in infants with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004 Within-day repeatability of fractional exhaled nitric oxide in severe asthma Source: Virtual Congress 2020 – Lung function tests and exhaled biomarkers Year: 2020 Standardization of pulmonary diffusing capacity for nitric oxide Source: International Congress 2017 – ERS statements and technical standards on diagnosis and monitoring Year: 2017 Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 Same-day repeatability of fractional exhaled nitric oxide in severe asthma Source: Eur Respir J, 57 (5) 2003391; 10.1183/13993003.03391-2020 Year: 2021 Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients Source: Eur Respir J 2001; 17: 1267-1270 Year: 2001 Exhaled nitric oxide is not reduced in infants with cystic fibrosis Source: Eur Respir J 2006; 27: 350-354 Year: 2006 Exhaled nitric oxide in patients with idiopathic pulmonary fibrosis and pulmonary hypertension Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008 A 2-year follow-up of exhaled nitric oxide (FeNO) and pulmonary function tests in young patients with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 538s Year: 2001 Airway acidification and exhaled nitric oxide in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003 Antibiotic treatment decreases exhaled nitric oxide levels in cystic fibrosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 384s Year: 2004 Early detection of emphysema with the nitric oxide diffusion capacity Source: Eur Respir J 2007; 30: Suppl. 51, 8s Year: 2007 Fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease Source: International Congress 2019 – FeNO in airway diseases and asthma-COPD overlap identification Year: 2019 Diffusing capacity for nitric oxide and capillary blood volume in patients with idiopathic interstitial pneumonia Source: Annual Congress 2008 - Pulmonary mechanics and gas exchange Year: 2008 The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003 Fractional exhaled nitric oxide levels in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2016 – Asthma, bronchiectasis, and the risk factors for respiratory morbidity Year: 2016